The acquisition will result in a new DLS division called HudsonAlpha Discovery that will provide a range of services to the pharma, biotech, and diagnostics industries.
HudsonAlpha's Genome Gateway collects family histories and facilitates secure communication between patients, clinicians, and researchers.
PyxisMap, unveiled at the recent ISMB conference, might soon be able to remove the human element from finding causal variants for rare diseases.
The funding will help support the whole-genome and RNA sequencing of Alzheimer's disease patients to advance biomarker development.
CFDRC obtained iXG's high-throughput antimicrobial discovery platform, EMAD (extremophilic microbiome antimicrobial discovery).
The project seeks to understand how genome sequencing as a first-line diagnostic in infants with likely hereditary disorders can impact long-term health outcomes.
HudsonAlpha researchers analyzed the genomes of parents whose children were in a study of developmental delay and intellectual disability for secondary findings.
Speakers at HudsonAlpha's Genomic Medicine Conference said while sequencing results sometimes result in a diagnosis and change in care, they often have no consequence.
HudsonAlpha's Greg Barsh described results from a Clinical Sequencing Exploratory Research project during the institute's ongoing Genomic Medicine Conference.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.